On September 21, 2022, the Board of Directors of CytomX Therapeutics, Inc. designated Chris Ogden, the Company's Senior Vice President, Finance and Accounting, to assume the responsibilities of principal financial officer and principal accounting officer, effective immediately, in connection to the planned departure of Carlos Campoy, the Company's SVP, Chief Financial Officer and former principal financial officer and principal accounting officer, whose employment is expected to terminate effective as of September 30, 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.455 USD | -41.41% | -45.67% | +57.74% |
02:01pm | Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3 | MT |
May. 08 | Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.74% | 284M | |
+2.73% | 108B | |
+9.25% | 105B | |
-0.29% | 23.46B | |
-14.37% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-7.52% | 17.19B | |
+6.10% | 13.99B | |
+36.02% | 12.53B |
- Stock Market
- Equities
- CTMX Stock
- News CytomX Therapeutics, Inc.
- CytomX Therapeutics, Inc. Announces Executive Changes